The global advanced drug delivery systems market is projected to grow from $255 billion in 2024 to $439.7 billion by 2034 at a 5.6% CAGR. Cardiovascular disease applications dominate with 37.8% market share, while North America leads regionally with 41.3% of the market. Emerging technologies include 3D-printed drug implants, smart hydrogels, and magnetic nanofiber platforms.
Multiple institutional investors modified their Moderna Inc positions during recent quarters, with some funds increasing stakes while others reduced or exited positions, according to 13F filings.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
Moderna has settled with Arbutus and Genevant, facing a potential $1.3 billion liability contingent on Federal Circuit's decision. Multiple institutional investors have increased their stakes in the biotech company during recent quarters.
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
Healthcare systems worldwide are addressing polypharmacy as a major public health issue, with new guidance emphasizing person-centered medication reviews and risk mitigation strategies across multiple clinical settings including infectious disease care.
The global stem cell therapy market is projected to grow from $18.13 billion in 2025 to $59.70 billion by 2035 at a 12.66% CAGR, driven by chronic disease prevalence and regenerative medicine advances.
Drug discovery outsourcing, preparative chromatography, and Latin America point-of-care diagnostics markets are forecast to grow at CAGRs between 7.5% and 8.2% through 2031, driven by biologics expansion and chronic disease prevalence.
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Moderna posted Q4 2025 revenue of $678 million, beating analyst estimates despite a 29.8% year-over-year decline. The company reduced operating expenses by 31% while facing FDA refusal to file its flu vaccine application.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07069400 |
An International Observational Study of Adults With Acute Infection |
RECRUITING | |
| NCT06827106 |
Dose-Quality Study in the Temporal Bone Computed Tomography in Routine Care |
COMPLETED | |
| NCT06574776 |
Prevalence and Associated Mortality of Infections by Multidrug-Resistant Organisms in Adults Intensive Care Units |
COMPLETED | |
| NCT06564194 |
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06510699 |
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial |
RECRUITING | PHASE2 |
| NCT06492187 |
Triage Survey for Infectious Disease Eligibility |
RECRUITING | |
| NCT06426147 |
L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) |
RECRUITING | NA |
| NCT06422338 |
A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients) |
RECRUITING | NA |
| NCT06410053 |
The All Ireland Infectious Diseases Cohort Project |
RECRUITING | |
| NCT06211621 |
Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic |
COMPLETED |
